The fact that lenacapavir will soon be available to patients is a testament to the strength of America's biopharmaceutical ...

Psychiatric medication is controversial. While most recognise that mental health problems are caused by a tangle of psychological, social and biological factors, debates about solutions are polarised ...

The AI in Life Science Market is anticipated to experience a remarkable compound annual growth rate (CAGR) of around 25% in ...

New Delhi: Shares of Glenmark Pharmaceuticals Ltd on Friday jumped 10 per cent after the firm said it has signed a deal with ...

Europe Pharmaceutical Drugs industry 2025 The Europe Pharmaceutical Drugs Market size is valued at USD 450 billion in 2025 and is expected ...

AbbVie and IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), have ...

DIADEME’ project awarded €6.5 million in government funding via France 2030, enabling Ciloa to advance development of its bio-drug APN-sEV (Adiponectin associated with exosomes), the world’s only ...

Weight-loss drugs have surged in popularity, promising rapid results with regular injections. Now, researchers from Japan report a way ...

To mark Ophthalmology Times' 50th anniversary, we invited top experts to reflect on the most significant innovations in ...

Florida’s importation program hasn’t brought in a single Canadian drug. It’s not cost-effective and it could be dangerous.

Google DeepMind subsidiary, Isomorphic Labs, has said it is ready to conduct human trials for drugs developed using its AlphaFold AI technology.

More patient-centric study design, using mHealth for longer-term monitoring, will address many of the inherent challenges in conducting pivotal clinical trials in rare diseases, argues Elin Haf ...